🏆 Deal of the Week · CW 12/2024
Nouscom raised EUR 75.8 million in a Series C round; the valuation was not disclosed. The round was supported by a broad syndicate of eleven investors spanning Europe and North America. This financing will advance the company's neoantigen-targeted cancer immunotherapy programmes through continued clinical development.
Nouscom — key deal facts
| Company | Nouscom |
| Founded | 2015 |
| Headquarters | Basel, Switzerland |
| Amount raised | EUR 75.8M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series C |
| Investors | 5AM Ventures Andera Partners Angelini Ventures Bpifrance EQT life science Indaco Venture Partners M Ventures Panakes Partners Revelation Partners Versant Ventures XGEN Venture |
| Sectors | Biotechnology |
Who invested in Nouscom?
The Series C was backed by 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, EQT Life Science, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGEN Venture. The syndicate is notable for combining specialist life science funds from the United States, France, Germany, Italy, and Switzerland alongside a French public investment bank. This cross-border investor composition reflects sustained institutional confidence in Nouscom's oncology platform across multiple geographies.
What does Nouscom do?
Nouscom is a clinical-stage biotechnology company founded in 2015 and headquartered in Basel, Switzerland, with additional operations in Rome, Italy. The company develops neoantigen-targeted cancer immunotherapies using a proprietary platform built on engineered viral vectors derived from primate adenovirus and Modified Vaccinia Virus Ankara. Its lead programmes include NOUS-209, an off-the-shelf neoantigen vaccine targeting tumours with microsatellite instability, and NOUS-PEV, a personalised neoantigen vaccine designed to target mutations unique to an individual patient's tumour. The platform was co-founded by Riccardo Cortese, MD, PhD, a scientist previously associated with Okairos.
Nouscom valuation & multiples
No existing multiples analysis was provided for this deal. Once revenue and EBITDA benchmarks become available for Nouscom, the transaction can be assessed against prevailing EV/Sales and EV/EBITDA ranges for clinical-stage biotechnology companies. Explore Venionaire DealMatrix's biotechnology sector multiples pages for current valuation reference ranges across comparable oncology and immunotherapy transactions.
Explore the benchmarks: Series C.
Frequently asked questions
How much did Nouscom raise in its Series C?
Nouscom raised EUR 75.8 million in its Series C round, recognised as Deal of the Week in KW 12/2024.
What is Nouscom's valuation?
Nouscom's valuation was not disclosed in connection with this Series C financing.
Who invested in Nouscom?
The round was backed by 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, EQT Life Science, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGEN Venture.
When was Nouscom founded and where is it based?
Nouscom was founded in 2015 and is headquartered in Basel, Switzerland, with additional operations in Rome, Italy.
Source: original announcement — read the full report.